CA
CLDX icon

CapWealth Advisors’s Celldex Therapeutics CLDX Stock Holding History

CapWealth Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-3
Closed -$2K – 369
2013
Q3 		$2K Buy
+3
New +$1.03K ﹤0.01% 415

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

CapWealth Advisors's CLDX Position: Q4 2013 in Review

CapWealth Advisors sold out of Celldex Therapeutics (CLDX) in Q4 2013, closing a stake of 3 shares — an estimated $2K sold.

CapWealth Advisors first reported a position in CLDX in Q3 2013 and held it in 1 quarter. The position peaked at $2K in Q3 2013. 162 funds tracked by Wall St. Rank hold CLDX as of Q4 2013.

  • CapWealth Advisors reported no remaining Celldex Therapeutics position as of Q4 2013 after selling out during the quarter.
  • CapWealth Advisors sold 3 Celldex Therapeutics shares in Q4 2013, an estimated $2K.
  • CapWealth Advisors first reported a position in Celldex Therapeutics in Q3 2013 and held it in 1 quarter.
  • CapWealth Advisors's Celldex Therapeutics position peaked at $2K in Q3 2013.
  • 162 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2013.

Based on CapWealth Advisors's 13F filing for Q4 2013, filed 13 Feb 2014.